title: Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
abstract: OBJECTIVE
  To determine whether symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain.
  
  
  METHODS
  Patients who complained of chest pain, but had normal coronary angiography, were asked to undergo upper endoscopy. Those without gastric and oesophageal lesions were recruited for 24-h ambulatory oesophageal pH monitoring, and were randomly given lansoprazole 30 mg or placebo, both daily for 4 weeks. Chest pain symptoms were recorded before and 1 month after treatment on a locally validated questionnaire. The symptom score was calculated by multiplying the severity and frequency of the symptom, and symptom improvement was defined as > 50% reduction in symptom score.
  
  
  RESULTS
  Overall, 68 patients, 36 on lansoprazole and 32 on placebo, completed the trial. The symptom score was reduced significantly in both groups (P < 0.001). In the lansoprazole group, more patients with than without abnormal reflux showed symptom improvement (92% vs. 33%; odds ratio = 22; 95% confidence interval, 2.3-201.8; chi2 = 10.9; P = 0.001), giving a sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 92%, 67%, 58%, 94% and 75%, respectively. In the placebo group, the rates of symptom improvement were similar between those with and without abnormal reflux (33% vs. 35%, P = N.S.).
  
  
  CONCLUSIONS
  Treatment with lansoprazole is a useful test in diagnosing endoscopy-negative gastro-oesophageal reflux disease in Chinese patients with non-cardiac chest pain.
authors.affiliation: Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, China. hhxxia@hku.hk
authors.forename: H H X
authors.initials: HH
authors.lastname: Xia
authors.forename: K C
authors.initials: KC
authors.lastname: Lai
authors.forename: S K
authors.initials: SK
authors.lastname: Lam
authors.forename: W H C
authors.initials: WH
authors.lastname: Hu
authors.forename: N Y H
authors.initials: NY
authors.lastname: Wong
authors.forename: W M
authors.initials: WM
authors.lastname: Hui
authors.forename: C P
authors.initials: CP
authors.lastname: Lau
authors.forename: W H
authors.initials: WH
authors.lastname: Chen
authors.forename: C K
authors.initials: CK
authors.lastname: Chan
authors.forename: W M
authors.initials: WM
authors.lastname: Wong
authors.forename: B C Y
authors.initials: BC
authors.lastname: Wong
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000328:Adult; D000368:Aged; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D002637:Chest Pain / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005764:Gastroesophageal Reflux / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D005773:Gastroscopy / Q000379:methods; D006801:Humans; D006863:Hydrogen-Ion Concentration; D064747:Lansoprazole; D008297:Male; D008875:Middle Aged; D009853:Omeprazole / Q000031:analogs & derivatives / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D011446:Prospective Studies
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000897:Anti-Ulcer Agents; D064747:Lansoprazole; D009853:Omeprazole